ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Vigil Neuroscience Inc

Vigil Neuroscience Inc (VIGL)

1.63
0.05
(3.16%)
Cerrado 24 Diciembre 3:00PM
1.63
0.00
(0.00%)
Fuera de horario: 4:00PM

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Último Precio
1.63
Postura de Compra
1.58
Postura de Venta
1.85
Volume Operado de la Acción
405,479
1.55 Rango del Día 1.715
1.54 Rango de 52 semanas 6.06
Capitalización de Mercado [m]
Precio Anterior
1.58
Precio de Apertura
1.58
Última hora de negociación
Volumen financiero
US$ 661,318
Precio Promedio Ponderado
1.631
Volumen promedio (3 m)
193,241
Acciones en circulación
40,879,485
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.81
Beneficio por acción (BPA)
-2.02
turnover
-
Beneficio neto
-82.64M

Acerca de Vigil Neuroscience Inc

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple ther... Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Mostrar más

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sitio web
Sede
Dover, Delaware, USA
Fundado
-
Vigil Neuroscience Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker VIGL. The last closing price for Vigil Neuroscience was US$1.58. Over the last year, Vigil Neuroscience shares have traded in a share price range of US$ 1.54 to US$ 6.06.

Vigil Neuroscience currently has 40,879,485 shares in issue. The market capitalisation of Vigil Neuroscience is US$64.59 million. Vigil Neuroscience has a price to earnings ratio (PE ratio) of -0.81.

VIGL Últimas noticias

Vigil Neuroscience to Present at Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the...

Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update

- Final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP planned for first half of 2025 - - Data from Phase 1 clinical trial evaluating VG-3927 in Alzheimer’s Disease on...

Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference

WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.25-13.29787234041.881.891.545044641.66335911CS
4-1.37-45.6666666667331.544250072.05235131CS
12-1.73-51.48809523813.364.121.541932412.51671078CS
26-2.33-58.83838383843.964.971.543201813.74984386CS
52-2.02-55.34246575343.656.061.542308513.69862302CS
156-10.37-86.41666666671218.271.541200085.38116668CS
260-10.37-86.41666666671218.271.541200085.38116668CS

VIGL - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Vigil Neuroscience?
El precio actual de las acciones de Vigil Neuroscience es US$ 1.63
¿Cuántas acciones de Vigil Neuroscience están en circulación?
Vigil Neuroscience tiene 40,879,485 acciones en circulación
¿Cuál es la capitalización de mercado de Vigil Neuroscience?
La capitalización de mercado de Vigil Neuroscience es USD 64.59M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Vigil Neuroscience?
Vigil Neuroscience ha negociado en un rango de US$ 1.54 a US$ 6.06 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Vigil Neuroscience?
El ratio precio/beneficio de Vigil Neuroscience es -0.81
¿Cuál es la moneda de reporte de Vigil Neuroscience?
Vigil Neuroscience presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de Vigil Neuroscience?
El último beneficio anual de Vigil Neuroscience es USD -82.64M
¿Cuál es la dirección registrada de Vigil Neuroscience?
La dirección registrada de Vigil Neuroscience es 850 NEW BURTON ROAD, SUITE 201, DOVER, DELAWARE, 19904
¿Cuál es la dirección del sitio web de Vigil Neuroscience?
La dirección del sitio web de Vigil Neuroscience es www.vigilneuro.com
¿En qué sector industrial opera Vigil Neuroscience?
Vigil Neuroscience opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
BAOSBaosheng Media Group Holdings Ltd
US$ 7.10
(310.40%)
58.74M
HOURHour Loop Inc
US$ 4.40
(207.69%)
97.42M
GTIGraphjet Technology
US$ 0.61
(168.72%)
265.48M
CREVCarbon Revolution Public Ltd
US$ 9.16
(135.48%)
26.95M
AVGRAvinger Inc
US$ 1.45
(125.72%)
107.53M
SLGLSol Gel Technologies Ltd
US$ 0.9798
(-40.62%)
3.07M
DRCTDirect Digital Holdings Inc
US$ 3.71
(-32.55%)
23.82M
CHEKCheck Cap Ltd
US$ 1.55
(-31.11%)
3.49M
SYTASiyata Mobile Inc
US$ 0.5178
(-30.83%)
2.63M
BTFValkyrie ETF Trust II CoinShares Bitcoin and Ether Stratagy ETF
US$ 15.47
(-30.38%)
147.98k
SVMHSRIVARU Holding Ltd
US$ 0.0338
(20.71%)
280.27M
GTIGraphjet Technology
US$ 0.61
(168.72%)
265.48M
LITMSnow Lake Resources Ltd
US$ 0.5849
(52.84%)
181.22M
LCIDLucid Group Inc
US$ 3.20
(3.23%)
108.75M
RGTIRigetti Computing Inc
US$ 11.35
(3.56%)
108.38M

VIGL Discussion

Ver más
Monksdream Monksdream 3 días hace
VIGL, under $2
👍️0
Monksdream Monksdream 4 meses hace
VIGL under $4
👍️0
Monksdream Monksdream 5 meses hace
VIGL under $5
👍️0
Monksdream Monksdream 6 meses hace
VIGL under $5
👍️0
MiamiGent MiamiGent 6 meses hace
Good insight.
👍️0
Zorro Zorro 6 meses hace
More than likely there is an announcement baked into this deal that will allow for the sale of those 7.44 shares at a profit.
👍️ 1
PonkenPlonken PonkenPlonken 6 meses hace
Those 3.80 dippers look pretty smart now ;)
👍️ 1
MiamiGent MiamiGent 6 meses hace
$VIGL At 12 noon:

Volume
13,927,465
90 Day Avg. Vol.
147,064

9.5 X's 90 DAV
👍️0
MiamiGent MiamiGent 6 meses hace
VIGL Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
GLOBENEWSWIRE
2:00 AM ET Jun-27-2024
- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock-

- Sanofi to receive an exclusive right of first negotiation for license of Company’s small molecule TREM2 agonist program, including VG-3927, currently in phase 1 clinical studies -

- Company expects proceeds to extend cash runway into 2026 -

WATERTOWN, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (VIGL.NaE) , a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, is pleased to announce that Sanofi has made a $40 million strategic investment in the Company at an as-converted price of $7.44 per share of common stock. Sanofi will purchase 537,634 of the Company’s Series A non-voting preferred shares, each share of which shall be convertible into ten shares of common stock. The Company will use the proceeds to fund its research and development activities.

“We are excited by this strategic investment from Sanofi, one of the world’s leading biopharmaceutical companies, for our research and development programs,” said Ivana Magovcevic-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. “We view Sanofi’s investment in Vigil as a validation of our promising precision medicine approach led by our two differentiated TREM2 modalities, iluzanebart and VG-3927, and Sanofi has provided valuable capital to help fund our pipeline. We look forward to the opportunity to work with Sanofi as we continue to advance our small molecule TREM2 agonist program.”

“Recent discoveries have highlighted the role of microglial signaling and neuroinflammation in neurodegenerative diseases. TREM2 is a well credentialed microglia target in this context,” said Erik Wallstroem, Sanofi's Global Head of Neurology Development. “The investment in Vigil strengthens our commitment to immunoscience and neuroimmunology.”

In connection with the equity investment, Vigil has granted Sanofi the exclusive right of first negotiation (ROFN) for an exclusive license, grant or transfer of rights to research, develop, manufacture and commercialize the Company’s small molecule TREM2 agonist program, including its clinical candidate, VG-3927. VG-3927 is currently being evaluated in a phase 1 clinical study for the potential treatment of Alzheimer’s disease.

Based on current projections, the Company expects that the proceeds from Sanofi’s investment will extend its cash runway into 2026.

About Vigil Neuroscience (VIGL.NaE)

Vigil Neuroscience (VIGL.NaE) is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Iluzanebart, Vigil’s lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) in genetically defined subpopulations.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements” of Vigil Neuroscience (VIGL.NaE) (“Vigil” or the “Company”) that are made pursuant to the safe harbor provisions of the federal securities laws.......
👍️0
PonkenPlonken PonkenPlonken 6 meses hace
they often do this in bio land on those that open a quarter+ up, reverse to 0 and then let them go the days after
👍️ 1
PonkenPlonken PonkenPlonken 6 meses hace
agree looking good down here
👍️0
MiamiGent MiamiGent 6 meses hace
VIGL In @ 3.83 for the scalp
👍️0
reena969 reena969 6 meses hace
VIGL: My guess is that the $7 price target for VIGL will be set for the 9:30 market opening, allowing the algorithm to gradually move it to that price point. 1498 in free left, I'll check back later.
Happy Trading
👍️0
tw0122 tw0122 6 meses hace
VIGL chop zone makes sense just read news $7.44 max pain 4.80- 7.41 chop zone

Vigil Neuroscience, Inc. (VIGL) announces that Sanofi (SNY) has made a $40 million strategic investment in the Company at an as-converted price of $7.44 per share of common stock. Sanofi will purchase 537,634 of the Company's Series A non-voting preferred shares, each share of which shall be convertible into ten shares of common stock. The Company will use the proceeds to fund its research and development activities.In connection with the equity investment, Vigil has granted Sanofi the exclusive right of first negotiation (ROFN) for an exclusive license, grant or transfer of rights to research, develop, manufacture and commercialize the Company's small molecule TREM2 agonist program, including its clinical candidate, VG-3927. VG-3927 is currently being evaluated in a phase 1 clinical study for the potential treatment of Alzheimer's disease.Based on current projections, the Company expects that the proceeds from Sanofi's investment will extend its cash runway into 2026.
👍️0
reena969 reena969 6 meses hace
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174665212

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174665196
👍️0
tw0122 tw0122 6 meses hace
VIGL 5.50s
👍️0
Monksdream Monksdream 7 meses hace
VIGL under $5
👍️0
Monksdream Monksdream 8 meses hace
VIGL under $3
👍️0
Terpi Terpi 1 año hace
This one trades this, looks like it may be finding a bottom.
👍️0

Su Consulta Reciente

Delayed Upgrade Clock